MetaCap

Sol-Gel Technologies (SLGL) vs Entrada Therapeutics (TRDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sol-Gel Technologies (SLGL) has outperformed Entrada Therapeutics (TRDA) over the past year, gaining 50.5% versus a loss of 57.0%. Over five years, SLGL leads with a -28.4% price change compared with -85.0% for TRDA. Sol-Gel Technologies is the larger company by market cap ($180.6 million vs $170.3 million), about 1.1 times the size.

Sol-Gel Technologies converts more of its revenue into profit, with a net margin of -31.6% versus -565.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SLGL+50.53%TRDA-56.97%
+179%+55%-68%
Nov 21, 20251 yearNov 20, 2026
SLGL-35.62%TRDA-86.73%
+12%-44%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SLGL versus TRDA key metrics
MetricSLGLTRDA
Share price$55.17$4.35
Market cap$180.63M$170.30M
1-day change+2.02%-6.25%
YTD return+30.92%-57.68%
1-year return+50.53%-56.97%
5-year return-28.44%-84.95%
EPS (TTM)$-5.22$-3.84
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$19.39M$25.42M
Revenue growth (YoY)+68.04%-87.94%
Net income (latest FY)$-6.13M$-143.75M
Operating margin-38.88%-621.13%
Net margin-31.60%-565.48%
52-week high$97.97$16.45
52-week low$34.47$4.11
Distance from 52-week high-43.69%-73.56%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+181.86%+308.05%
Average volume47.38K401.15K
Shares outstanding3.27M39.15M
Employees28152
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SLGL has outperformed TRDA by 107.5 percentage points over the past year.
  • Sol-Gel Technologies is more profitable, keeping -31.6 cents of every revenue dollar as net income versus -565.5 cents for Entrada Therapeutics.
  • Sol-Gel Technologies grew revenue faster in its latest fiscal year (+68.04% vs -87.94%).

About Sol-Gel Technologies

SLGL stock →

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About Entrada Therapeutics

TRDA stock →

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees

SLGL vs TRDA FAQ

Which is bigger, Sol-Gel Technologies or Entrada Therapeutics?

Sol-Gel Technologies (SLGL) is larger, with a market capitalization of $180.63M compared with $170.30M for Entrada Therapeutics (TRDA).

Which stock has performed better over the past year, SLGL or TRDA?

SLGL returned +50.53% over the past 12 months, compared with -56.97% for TRDA (price return, excluding dividends). Past performance does not predict future results.

Are Sol-Gel Technologies and Entrada Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons